Why ISO 14971 Matters More Than Ever

EU MDR significantly elevated the importance of risk management compared to the previous MDD. Under MDR, the benefit-risk analysis must demonstrate that benefits outweigh residual risks — and this analysis must be maintained and updated throughout the device's commercial life. A superficial risk management file that lists hazards without genuine analysis of their probability and severity, without meaningful risk controls, and without post-market surveillance feedback will be rejected by Notified Bodies and regulators. ISO 14971:2019 (the current version) must be the framework.

The ISO 14971 Risk Management Process

The standard defines a structured process: (1) Risk Management Plan — defines the scope, responsibilities, criteria for risk acceptability, and activities required for the specific device, (2) Risk Analysis — systematic identification of hazards and estimation of risk for each hazard using a combination of probability and severity of harm, (3) Risk Evaluation — comparing estimated risk against acceptability criteria defined in the plan, (4) Risk Control — implementing measures to reduce unacceptable risks to ALARP (as low as reasonably practicable), (5) Residual Risk Evaluation — confirming remaining risks are acceptable, (6) Overall Residual Risk Evaluation — confirming that the device's overall residual risk-benefit ratio is favourable, (7) Risk Management Review — ensuring the process has been correctly applied, (8) Production and Post-Production Activities — ongoing risk monitoring and feedback loop.

Risk Analysis: Identifying Hazards Systematically

Risk analysis requires systematic identification of all foreseeable hazards associated with the device across its entire intended use and reasonably foreseeable misuse. Common methods include FMEA (Failure Mode and Effects Analysis), FTA (Fault Tree Analysis), and hazard analysis (what-if analysis). ISO 14971 requires that analysis cover: energy hazards (electrical, mechanical, thermal), biological hazards (biocompatibility, sterility), software hazards (incorrect output, system failure), and use-related hazards (misuse, use errors identified through IEC 62366 usability engineering).

Risk Acceptability Criteria: Defining Your Policy

The Risk Management Plan must define explicit risk acceptability criteria — the levels of risk that are considered acceptable, broadly acceptable, and as low as reasonably practicable (ALARP). These criteria are typically expressed as a risk matrix combining probability of harm (rare to frequent) and severity of harm (negligible to catastrophic). Risk criteria must be justified — typically by reference to applicable standards, comparable device data, and stakeholder expectations. Notified Bodies scrutinise risk acceptability criteria carefully; criteria that are too permissive without justification will be challenged.

Risk Control Hierarchy

ISO 14971 requires that risk controls be implemented in a specific order of priority: (1) Inherently safe design — eliminate the hazard through design choices, (2) Protective measures — add guards, alarms, or protection mechanisms, (3) Information for safety — labelling, warnings, and Instructions for Use. Risk controls that only use warnings and instructions for safety are considered the least effective — regulators prefer inherent design solutions. All risk controls must be verified to confirm they work as intended and must be assessed for introduction of new risks.

Benefit-Risk Analysis Under EU MDR

EU MDR Annex I requires manufacturers to demonstrate that the benefits of the device outweigh its residual risks. This benefit-risk analysis must be quantitative where possible, must consider the benefits for the intended patient population, and must be compared with available alternatives (including non-device alternatives). The benefit-risk analysis is a living document — post-market data must feed back into it and the analysis must be updated if new safety data emerges.

Common Deficiencies in Risk Management Files

The most frequent deficiencies identified by Notified Bodies include: (1) hazard identification that is too generic (e.g., 'electrical shock' without analysis of specific device circuits), (2) risk estimates not supported by data — probability values assigned arbitrarily without reference to testing, literature, or complaint data, (3) risk controls not verified — no test evidence that the control actually reduces risk, (4) no post-market data feedback into the risk management file, (5) benefit-risk analysis that is qualitative only ('benefits outweigh risks') without quantitative justification.

Conclusion

ISO 14971 risk management is the spine of the medical device technical file. Done well, it demonstrates to regulators that you have genuinely thought through how your device could harm patients and what you have done about it. Turkish manufacturers who invest in building robust, evidence-based risk management systems will find regulatory reviews more successful and post-market issues more manageable.